Latest News

Biosimilar to infliximab shows equivalent safety and efficacy for treating Crohn's disease

A biosimilar of infliximab, CT-P13, has equivalent safety and efficacy to that of the anti-tumor necrosis factor (TNF) monoclonal antibody for treating Crohn’s disease in infliximab-naïve patients. Findings from a comparative equivalence cohort study are published in Annals of Internal Medicine.

Source link

Related posts

STAT Plus: Sen. Hatch to colleagues: Don’t let Trump tie drug prices to what other countries pay


U.S. Birth Rates Still Dropping, Moms Still Older


Researchers develop promising new stroke therapy


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy